Amicus Therapeutics (FOLD) Misses Q1 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall St set for higher open as AI stocks rise, oil slides
- Streamflation drives 39% of Americans to cancel streaming in 6 months
Amicus Therapeutics Announces First Quarter 2015 Financial Results and Corporate Updates
May 5, 2015 4:00 PM EDTMarketing Submissions for Migalastat Monotherapy for Fabry Disease on Track for 2Q15 in Europe and 2H15 in United States Net Cash Spend Guidance Updated to $100-$110 Million on Accelerated Commercialization and Manufacturing Next-Generation Pompe ERT Set to Enter Clinic in 2H15
CRANBURY, N.J., May 5, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced financial results for the first quarter ended March... More
